KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Announces 1,000th Procedure Utilizing its Innovative Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”) System, the First Pediatric-Specific Solution Optimized to Treat Fractures and Deformities

OrthoPediatrics Corp. Announces 1,000th Procedure Utilizing its Innovative Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”) System, the First Pediatric-Specific Solution Optimized to Treat Fractures and Deformities

WARSAW, Ind., Sept. 03, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced completion of the 1,000th surgery utilizing its Pediatric Nailing Platform | FEMUR (“PNP | FEMUR”), the first system specifically designed and developed to address the unique pediatric anatomies when treating femoral fractures and deformity correction procedures.

PNP | FEMUR, which received FDA 510(k) clearance in 2018, is an intramedullary nailing system to stabilize fractures and deformity correction osteotomies. It features a full suite of innovative instrumentation offering two distinct child and adolescent implant options optimized to handle the unique needs of small stature trauma and deformity procedures. The system’s enhanced child sized nails range from 7-9mm and the new adolescent sized nails range from 9-12mm. The PNP system offers the widest range of nail and screw options coupled with unique size specific nail features implanted through proprietary instrumentation; providing a full spectrum, all-inclusive system to treat children of any age and size. 

“We are proud of the innovative solutions that evolved from an impressive engineering team working closely with world renowned physician advisors to solve unmet pediatric patient and surgical needs. The PNP|FEMUR is actually OP’s 2nd generation nailing system, which improved upon almost a decade of learnings from the original PediNail system. Being the first to design and launch a pediatric nailing system, we have an obligation to take those learnings and improve,” commented Joe Hauser, Vice President of OrthoPediatrics’ Trauma & Deformity Correction business. “The thousandth implant represents a great milestone for our company, the many children that have been treated, and their families. Also, it displays our never-ending dedication to improving our own pediatric implant systems.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit .

Investor Contact

The Ruth Group

Emma Poalillo

(646) 536-7024

EN
03/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annu...

OrthoPediatrics Corp. Continued Leading Sponsorship at 2025 POSNA Annual Meeting Reinforced Long-Term Commitment as Emerald Sponsor WARSAW, Ind., May 14, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the 2025 Pediatric Orthopaedic Society of North America (“POSNA”) annual meeting as an Emerald Sponsor. At the Annual Meeting, the Company will highlight its growing portfolio of pediatric-specific solutions, including...

 PRESS RELEASE

OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and...

OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance First Quarter 2025 Revenue Increased 17% Year-over-Year WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of...

 PRESS RELEASE

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ ...

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company’s 5th FDA approval in 2025. 3P Pediatric Plating Platform Hip System is a new plate and scre...

 PRESS RELEASE

OrthoPediatrics Corp. to Report First Quarter Financial Results on May...

OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025 WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so...

 PRESS RELEASE

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of Verte...

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children. VerteGlide is a guided growth technology designed for children with Early Onset S...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch